4450156 Pharmaceutical composition containing a derivative of ortho-aminobenzoic acid as an active ingredient

4450156 Pharmaceutical composition containing a derivative of ortho-aminobenzoic acid as an active ingredient

xiv New Patents precluded. The stopper is preferably molded together with the cap, being connected to the cap by an integral strap. 4450156 PHARMAC...

83KB Sizes 62 Downloads 170 Views

xiv

New Patents

precluded. The stopper is preferably molded together with the cap, being connected to the cap by an integral strap.

4450156 PHARMACEUTICAL COMPOSITION CONTAINING

A

DERIVATIVE OF ORTHOAMINOBENZOIC A C I D A S A N ACTIVE INGREDIENT Chikao Yoshikumi, Yoshio Ohmura, Fumio Hirose, Masanori Ikuzawa, Kenichi Matsunaga, Takayoshi Fujii, Minoru Ohhara, Takao Ando, Higashi, Kunitachi shi, Tokyo, Japan

COO2R

4450168

Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: See Patent for Chemical Structure wherein 1R denotes one member selected from the group consisting of the residual groups formed by removing OH at l(alpha) or l(beta) position from arabinose, xylose, glucose, galactose, rhamnose and mannose, and 2R denotes hydrogen or methyl group, or a pharmaceutically acceptable salt thereof.

PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS HAVING ACTION ON HISTAMINE RECEPTORS David E Bays, Roge Hayes, Hertfordshire, United Kingdom assigned to Glaxo Group Limited

R3\

N--N R4 RIR2NCH2--~O(CH2)mNH--~ .~-- AIkOCIIOR5 [ N

4450162 PYRIMIDINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM Toshihar Kamioka, Isao Nakayama, Takeo Honda, Takash Kobayashi, Tokio Obata, Katsutoshi Fujii, Mikio Kojima, Yuji Akiyoshi, Hiromachi, Japan assigned to Sankyo Company Limited; Ube Industries Limit

R3\ N / / ~ ' ~

(wherein: R1 and R2 are the same or different and each represents a C1-C6 alkyl group or R1 and R2 together represent a C3-C5 alkylene group; R3 represents a hydrogen atom or a C1C6 alkyl group; n is 0, 1 or 2; and R4 represents a C1-C6 alkyl group, a C1-C6 alkoxy group, a C1C6 haloalkyl group, a halogen atom, a nitro group, a C 1-C6 alkanesulphonyl group, a cyano group, a carboxy group or a C2-C7 alkoxycarbonyl group and, when n is 2, the two groups represented by R4 may be the same or different or they may together represent a methylenedioxy group) and pharmaceutically acceptable acid addition salts thereof have been found to have strong antidepressant activity, with low toxicity and very few side-effects. The compounds may be formulated in conventional pharmaceutical compositions for administration by various routes and may be prepared by reacting a 4halopyrimidine with aniline or an aniline derivative.

(R4)n

New 4-anilinopyrimidine derivatives of formula (I): See Patent for Chemical Structure (I)

Compounds of general formula (I) See Patent for Chemical Structure (I) and physiologically acceptable salts and hydrates thereof in which R1 and R2 each represent methyl groups or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexamethylenimino group; R3 represents hydrogen or methyl; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; R4 represents a hydrogen atom and R5 represents a CI-4 alkyl group; or R4 and R5 together with the atoms to which they are attached form a tetrahydropyranyl ring; and either n is zero, X is oxygen, m is 3 or 4, and Q is a benzene ring linked through the 1- and 3- positions; or n is 1, X is sulphur, m is 2, and Q is a furan ring linked through the 2- and 5- positions with optionally a methyl substituent on the carbon atom adjacent to the group R1R2NCH2, or Q is a thiophene ring linked through the 2- and 4- positions with the group R1R2NCH2 in the 2- posi-